GDS Wealth Management Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

GDS Wealth Management increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 41,595 shares of the medical research company’s stock after buying an additional 5,244 shares during the quarter. GDS Wealth Management’s holdings in IQVIA were worth $9,624,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in IQV. AdvisorNet Financial Inc lifted its position in IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares during the period. BKM Wealth Management LLC acquired a new stake in IQVIA during the 4th quarter worth approximately $32,000. Activest Wealth Management acquired a new stake in IQVIA during the 4th quarter worth approximately $35,000. CVA Family Office LLC acquired a new stake in IQVIA during the 4th quarter worth approximately $43,000. Finally, CoreFirst Bank & Trust acquired a new stake in IQVIA during the 3rd quarter worth approximately $44,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on IQV. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Truist Financial reduced their price target on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a report on Friday, May 3rd. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Evercore ISI reduced their price target on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a report on Friday, May 3rd. Finally, SVB Leerink assumed coverage on IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price target for the company. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $257.57.

IQVIA Stock Performance

Shares of NYSE IQV traded up $1.32 during midday trading on Thursday, hitting $229.20. 643,740 shares of the company’s stock were exchanged, compared to its average volume of 961,353. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The stock’s 50 day moving average price is $242.48 and its 200-day moving average price is $225.08. The firm has a market cap of $41.76 billion, a P/E ratio of 31.31, a PEG ratio of 2.16 and a beta of 1.52. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business’s revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.54 earnings per share. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.12 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock worth $10,331,003 over the last ninety days. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.